Report : Asia Pacific Medical Perfusion Technology Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Technique (Hypothermic Machine Perfusion and Normothermic Machine Perfusion), Organ Type (Heart, Lung, Kidney, Liver, and Others); Component (Perfusion Pumps, Oxygenators, Heart-Lung Machines, Monitoring Systems, Cannulas, and Others)
Hypothermic Machine Perfusion Segment Held Largest Share of Technique in Asia Pacific Medical Perfusion Technology Market in 2019
According to a new market research study of ‘Asia Pacific Medical Perfusion Technology Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by technique, organ type, and component’ the Asia Pacific Medical perfusion technology market is expected to reach US$ 212.3 million in 2027 from US$ 148.6 million in 2019. The market is estimated to grow with a CAGR of 4.7% from 2020-2027. The report provides trends prevailing in the Asia Pacific Medical perfusion technology market and the factors driving market along with those that act as hindrances.
Based on the technique, the medical perfusion technology market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment held the largest share of the market whereas the normothermic machine perfusion segment is expected to dominate the market share with the highest CAGR during the forecast period. Hypothermic machine perfusion (HMP) has been developed to increase the storage time and reliability of the preservative process for the transplantable organ. The goal of HMP is to allow redundant organs to continue to operate without human intervention. This treatment method includes a continuous perfusion of the liver preservation solution, which provides nutrients and can also retain oxygen and removes toxic metabolites from the organ in patients. The hypothermia caused in the procedure results in a decrease in cellular function that helps regulate the ability of the organ to survive any subsequent effects of ischemia and reperfusion damage (IRI). The HMP procedure is approved for the safety of the kidneys in the medical world. Several experimental studies have demonstrated their credibility in prolonging the survival of marginal organs (such as from older donors, donors with morbidities, donors with a history of smoking, and donation after cardiac death).
The growth of this market is estimated to grow owing to key driving factors such as the rising prevalence of cardiovascular conditions and the increasing practice of organ transplantation. However, the market is expected experiencing slow growth during the forecast period owing to the expensive organ transplant surgeries.
Medtronic, LivaNova PLC, Terumo Corporation, TransMedics, Organ Recovery Systems, Xenios AG - a Fresenius Medical Care company are among the leading companies operating in the Asia Pacific Medical perfusion technology market.
The report segments Asia Pacific Medical Perfusion Technology Market as Follows:
- Hypothermic Machine Perfusion
- Normothermic Machine Perfusion
By Organ Type
- Perfusion Pumps
- Heart-Lung Machines
- Monitoring Systems
- Asia Pacific
- South Korea
- Rest of Asia Pacific
Contact Person: Sameer Joshi
Email Id: email@example.com